These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 33939281)

  • 1. First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component.
    Zhou YW; Long YX; Chen Y; Liu JY; Pu D; Huang JY; Bi F; Li Q; Gou HF; Qiu M
    Cancer Med; 2021 May; 10(10):3388-3402. PubMed ID: 33939281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
    Catalano V; Bergamo F; Cremolini C; Vincenzi B; Negri F; Giordani P; Alessandroni P; Intini R; Stragliotto S; Rossini D; Borelli B; Santini D; Sarti D; Rocchi MBL; Lonardi S; Falcone A; Zagonel V; Mattioli R; Graziano F
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):493-501. PubMed ID: 31691872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
    Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
    Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
    Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.
    Bai L; Wang F; Li ZZ; Ren C; Zhang DS; Zhao Q; Lu YX; Wang DS; Ju HQ; Qiu MZ; Wang ZQ; Wang FH; Xu RH
    Medicine (Baltimore); 2016 Dec; 95(51):e4531. PubMed ID: 28002313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
    Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
    JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
    Yu Y; Ying J; Zhang W; Li W; Sun Y; Yang L; Cui C; Zeng Y; Zhou A
    Asia Pac J Clin Oncol; 2019 Jun; 15(3):128-135. PubMed ID: 30693649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer.
    Hsu HC; Liu YC; Wang CW; Chou WC; Hsu YJ; Chiang JM; Lin YC; Yang TS
    Cancer Med; 2019 Jul; 8(7):3437-3446. PubMed ID: 31090176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy.
    Takada S; Sagawa T; Fujikawa K; Tahatsu K; Fukai Y; Hashishita H; Takahashi Y; Endo M
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2325-2330. PubMed ID: 30141310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
    Burge M; Semira C; Lee B; Lee M; Kosmider S; Wong R; Shapiro J; Ma B; Dean AP; Zimet AS; Steel SA; Lok SW; Torres J; Eastgate M; Wong HL; Gibbs P
    Clin Colorectal Cancer; 2018 Sep; 17(3):e593-e599. PubMed ID: 29958812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial.
    Li S; Li X; Zhu Q; Gao J; Zhu C; Zhu L
    Cancer Control; 2024; 31():10732748241275012. PubMed ID: 39286935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
    Snyder M; Bottiglieri S; Almhanna K
    Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.
    Price T; Shen L; Ma B; Esser R; Chen W; Gibbs P; Lim R; Cheng AL
    Asia Pac J Clin Oncol; 2019 Aug; 15(4):225-230. PubMed ID: 31090260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.
    Houts AC; Ogale S; Sommer N; Satram-Hoang S; Walker MS
    J Gastrointest Cancer; 2019 Mar; 50(1):69-77. PubMed ID: 29168112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
    Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C
    Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
    Matsusaka S; Zhang W; Cao S; Hanna DL; Sunakawa Y; Sebio A; Ueno M; Yang D; Ning Y; Parekh A; Okazaki S; Berger MD; Ichikawa W; Mizunuma N; Lenz HJ
    Mol Cancer Ther; 2016 Jun; 15(6):1405-11. PubMed ID: 26983880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.
    Marques RP; Godinho AR; Heudtlass P; Pais HL; Quintela A; Martins AP
    J Cancer Res Clin Oncol; 2020 May; 146(5):1321-1334. PubMed ID: 32144533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis.
    Fan Q; Lv W; Xu Y; Dong Y; Xiang Z; Wang J
    Curr Pharm Des; 2020; 26(26):3171-3186. PubMed ID: 32067605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.